About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2012 (2012), Article ID 301975, 18 pages
http://dx.doi.org/10.1155/2012/301975
Review Article

Bone Sarcomas: From Biology to Targeted Therapies

1Department of Oncology for Children and Adolescents, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
2Inserm U957-EA 3822, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
3Oncopediatric Departement, CHU de Nantes, Boulevard Jacques Monod, 44093 Nantes, France
4Pediatric Onco-Hematology Department, EA 4438UdS, CHRU Strasbourg, Avenue Molière, 67000 Strasbourg, France
5Unité 830 INSERM, Institut Curie, Centre de Recherche, 26 rue d’Ulm, 75248 Paris Cedex 05, France
6Oncopediatric Departement, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France
7Oncopediatric Departement, Hôpital La Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France
8Department of Medical Oncology, Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, France

Received 1 July 2012; Accepted 10 October 2012

Academic Editor: R. Pollock

Copyright © 2012 Nathalie Gaspar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ladenstein, U. Pötschger, M. C. Le Deley et al., “Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3284–3291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Oberlin, M. C. L. Deley, B. N. G. Bui et al., “Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the french society of paediatric oncology (EW88 study),” British Journal of Cancer, vol. 85, no. 11, pp. 1646–1654, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Le Deley, J. M. Guinebretière, J. C. Gentet et al., “SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients,” European Journal of Cancer, vol. 43, no. 4, pp. 752–761, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. E. Pakos, A. D. Nearchou, R. J. Grimer, et al., “Prognostic factors and outcomes for osteosarcoma: an international collaboration,” European Journal of Cancer, vol. 45, no. 13, pp. 2367–2375, 2009.
  5. M. Stahl, A. Ranft, M. Paulussen et al., “Risk of recurrence and survival after relapse in patients with Ewing sarcoma,” Pediatric Blood and Cancer, vol. 57, no. 4, pp. 549–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Tirode, K. Laud-Duval, A. Prieur, B. Delorme, P. Charbord, and O. Delattre, “Mesenchymal stem cell features of Ewing tumors,” Cancer Cell, vol. 11, no. 5, pp. 421–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Benini, M. C. Manara, V. Cerisano et al., “Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects,” International Journal of Cancer, vol. 108, no. 3, pp. 358–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. V. Erkizan, V. N. Uversky, and J. A. Toretsky, “Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma,” Clinical Cancer Research, vol. 16, no. 16, pp. 4077–4083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Tanaka, T. Iwakuma, K. Harimaya, H. Sato, and Y. Iwamoto, “EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells,” Journal of Clinical Investigation, vol. 99, no. 2, pp. 239–247, 1997. View at Scopus
  10. A. Maksimenko, G. Lambert, J. R. Bertrand, E. Fattal, P. Couvreur, and C. Malvy, “Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides,” Annals of the New York Academy of Sciences, vol. 1002, pp. 72–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, “Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma,” Cancer Research, vol. 65, no. 19, pp. 8984–8992, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. J. Grohar, G. M. Woldemichael, L. B. Griffin et al., “Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening,” Journal of the National Cancer Institute, vol. 103, no. 12, pp. 962–978, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. V. Erkizan, Y. Kong, M. Merchant et al., “A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma,” Nature Medicine, vol. 15, no. 7, pp. 750–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Baruchel, A. Pappo, M. Krailo, et al., “A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group,” European Journal of Cancer, vol. 48, no. 4, pp. 579–585, 2012.
  15. P. J. Grohar, L. B. Griffin, C. Yeung et al., “Ecteinascidin 743 interferes with the activity of EWS-FLI1 in ewing sarcoma cells,” Neoplasia, vol. 13, no. 2, pp. 145–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Lau, J. G. Supko, S. Blaney et al., “A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study,” Clinical Cancer Research, vol. 11, no. 2 I, pp. 672–677, 2005. View at Scopus
  17. S. Delaloge, A. Yovine, A. Taamma et al., “Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1248–1255, 2001. View at Scopus
  18. A. Le Cesne, A. Yovine, J. Y. Blay et al., “A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials,” Investigational New Drugs, vol. 30, pp. 1193–1202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Mateo-Lozano, P. C. Gokhale, V. A. Soldatenkov, A. Dritschilo, O. M. Tirado, and V. Notario, “Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma,” Clinical Cancer Research, vol. 12, no. 22, pp. 6781–6790, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. W. D. Tap, “AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): phase II results,” Journal of Clinical Oncology, vol. 28, supplement, abstract 10001, p. 15s, 2010.
  21. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. S. Pappo, S. R. Patel, J. Crowley, et al., “R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4541–4547, 2010.
  23. H. Juergens, N. C. Daw, B. Geoerger, et al., “Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma,” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4534–4540, 2011.
  24. S. Malempati, B. Weigel, A. M. Ingle, et al., “Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 256–262, 2012.
  25. P. Anderson, K. Skubitz, R. Miller, et al., “Activity of SCH 717454 in subjects with relapsed osteosarcoma or Ewing’s sarcoma (study P04720),” in Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society, Abstract #35094, London, UK, 2007.
  26. A. L. Ho and G. K. Schwartz, “Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning?” Journal of Clinical Oncology, vol. 29, no. 34, pp. 4581–4583, 2011.
  27. K. Scotlandi, M. C. Manara, M. Serra et al., “Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival,” European Journal of Cancer, vol. 47, no. 8, pp. 1258–1266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Garofalo, M. C. Manara, G. Nicoletti et al., “Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling,” Oncogene, vol. 30, no. 24, pp. 2730–2740, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Gazitt, V. Kolaparthi, K. Moncada, C. Thomas, and J. Freeman, “Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways,” International Journal of Oncology, vol. 34, no. 2, pp. 551–561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Wan, A. Mendoza, C. Khanna, and L. J. Helman, “Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma,” Cancer Research, vol. 65, no. 6, pp. 2406–2411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Mora, E. Rodríguez, C. de Torres, et al., “Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome,” Pediatric Blood & Cancer, vol. 58, no. 4, pp. 532–538, 2012.
  32. M. Fouladi, F. Laningham, J. Wu et al., “Phase I study of everolimus in pediatric patients with refractory solid tumors,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4806–4812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. L. Spunt, S. A. Grupp, T. A. Vik et al., “Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors,” Journal of Clinical Oncology, vol. 29, no. 21, pp. 2933–2940, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. P. Chawla, A. P. Staddon, L. H. Baker, et al., “Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 78–84, 2012.
  35. S. P. Chawla, “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT),” Journal of Clinical Oncology, vol. 29, supplement, abstract 10005, 2011.
  36. A. Naing, P. LoRusso, S. Fu, et al., “Insulin Growth Factor-Receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors,” Clinical Cancer Research, vol. 18, no. 9, pp. 2625–2631, 2012.
  37. T. Kubo, S. Piperdi, J. Rosenblum et al., “Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma,” Cancer, vol. 112, no. 10, pp. 2119–2129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. S. Merchant, C. W. Woo, C. L. Mackall, and C. J. Thiele, “Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity,” Journal of the National Cancer Institute, vol. 94, no. 22, pp. 1673–1679, 2002. View at Scopus
  39. M. Hotfilder, C. Lanvers, H. Jürgens, J. Boos, and J. Vormoor, “C-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571),” Cancer Chemotherapy and Pharmacology, vol. 50, no. 2, pp. 167–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Chugh, J. K. Wathen, R. G. Maki, et al., “Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3148–3153, 2009.
  41. J. Chao, G. T. Budd, P. Chu et al., “Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRα-expressing ewing sarcoma family of tumors and desmoplastic small round cell tumors,” AntiCancer Research, vol. 30, no. 2, pp. 547–552, 2010. View at Scopus
  42. M. Bond, M. L. Bernstein, A. Pappo et al., “A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study,” Pediatric Blood and Cancer, vol. 50, no. 2, pp. 254–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. I. González, E. J. Andreu, A. Panizo et al., “Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis,” Clinical Cancer Research, vol. 10, no. 2, pp. 751–761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Timeus, N. Crescenzio, A. Fandi, A. Doria, L. Foglia, and L. C. di Montezemolo, “In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines,” Oncology Reports, vol. 19, no. 2, pp. 353–359, 2008. View at Scopus
  45. P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb, “Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo,” Clinical Cancer Research, vol. 15, no. 10, pp. 3416–3422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Aplenc, S. M. Blaney, L. C. Strauss et al., “Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 839–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Pignochino, G. Grignani, G. Cavalloni et al., “Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways,” Molecular Cancer, vol. 8, article 118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Grignani, E. Palmerini, and P. Dileo, “A phase II trial of sorafenib in relapsed and unresectable high-grade 10 osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study,” Annals of Oncology, vol. 23, no. 2, pp. 508–516, 2012.
  49. J. M. Maris, J. Courtright, P. J. Houghton et al., “Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 51, no. 1, pp. 42–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. G. DuBois, S. Shusterman, J. M. Reid, et al., “Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study,” Cancer Chemother Pharmacol, vol. 69, no. 4, pp. 1021–1027, 2012.
  51. S. G. DuBois, S. Shusterman, A. M. Ingle et al., “Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study,” Clinical Cancer Research, vol. 17, no. 15, pp. 5113–5122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. T. Keir, J. M. Maris, R. Lock et al., “Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program,” Pediatric Blood and Cancer, vol. 55, no. 6, pp. 1126–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Kumar, R. B. Mokhtari, R. Sheikh, et al., “Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor,” Clinical Cancer Research, vol. 17, no. 17, pp. 5656–5667, 2011.
  54. J. L. Glade Bender, A. Lee, P. C. Adamson, et al., “Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): a Children’s Oncology Group Phase I Consortium Trial,” Journal of Clinical Oncology, vol. 29, supplement, abstract 9501, 2011.
  55. T. Bachelot, C. Bourgier, C. Cropet, et al., “Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study,” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2718–2724, 2012.
  56. H. S. Rugo and S. Keck, “Reversing hormone resistance: have we found the golden key?” Journal of Clinical Oncology, vol. 30, no. 22, pp. 2707–2709, 2012.
  57. W. Fu, M. Le, B. Chu et al., “The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells,” Molecular Cancer Therapeutics, vol. 10, no. 6, pp. 1018–1027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. S. P. Chawla, V. S. Chua, L. Fernandez et al., “Phase I/II and phase II studies of targeted gene delivery In vivo: intravenous rexin-g for chemotherapy-resistant sarcoma and osteosarcoma,” Molecular Therapy, vol. 17, no. 9, pp. 1651–1657, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. M. Maris, C. L. Morton, R. Gorlick et al., “Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP),” Pediatric Blood and Cancer, vol. 55, no. 1, pp. 26–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. A. G. Morales, M. S. Brassesco, J. A. Pezuk et al., “BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity,” Anti-Cancer Drugs, vol. 22, pp. 995–1001, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. L. T. Vassilev, B. T. Vu, B. Graves et al., “In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2,” Science, vol. 303, no. 5659, pp. 844–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Tovar, J. Rosinski, Z. Filipovic et al., “Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1888–1893, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Sonnemann, C. D. Palani, S. Wittig et al., “Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells,” European Journal of Cancer, vol. 47, no. 9, pp. 1432–1441, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Javelaud and F. Besançon, “NF-κB activation results in rapid inactivation of JNK in TNFα-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-κB,” Oncogene, vol. 20, no. 32, pp. 4365–4372, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. C. D. Palani, J. F. Beck, and J. Sonnemann, “Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression,” Investigational New Drugs, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Bruheim, Y. Xi, J. Ju, and O. Fodstad, “Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide,” Clinical Cancer Research, vol. 15, no. 23, pp. 7161–7169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Puglisi, L. van Doorn, M. Blanco-Codesido, et al., “A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors,” Journal of Clinical Oncology, vol. 29, supplement, abstract 2518, 2011.
  68. G. Picarda, F. Lamoureux, L. Geffroy et al., “Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival,” Clinical Cancer Research, vol. 16, no. 8, pp. 2363–2374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Wang, D. Mandal, S. Wang et al., “Platelet-derived growth factor receptor β inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy,” Cancer, vol. 116, no. 16, pp. 3892–3902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. P. J. Kaplan-Lefko, J. D. Graves, S. J. Zoog et al., “Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types,” Cancer Biology and Therapy, vol. 9, no. 8, pp. 618–631, 2010. View at Scopus
  71. S. P. Chawla, A. C. Lockhart, N. Azad, et al., “Efficacy and safety of conatumumab plus AMG 479 in patients with advanced sarcoma,” in Proceedings of the CTOS Meeting, Chicago, Ill, USA, 2010.
  72. G. D. Demetri, A. Le Cesne, S. P. Chawla, et al., “First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study,” European Journal of Cancer, vol. 48, no. 4, pp. 547–563, 2012.
  73. P. J. Houghton, M. H. Kang, C. P. Reynolds, et al., “Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program,” Pediatr Blood Cancer, vol. 58, no. 4, pp. 636–639, 2012.
  74. S. V. Holt, K. E. Brookes, C. Dive, and G. W. J. Makin, “Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents,” Oncology Reports, vol. 25, no. 4, pp. 1177–1181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. J. C. Brenner, F. Y. Feng, S. Han, et al., “PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma,” Cancer Research, vol. 72, no. 7, pp. 1608–1613, 2012.
  76. Y. F. Wu, X. J. Liang, Y. Y. Liu et al., “+Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63,” Neoplasma, vol. 57, no. 6, pp. 501–506, 2010. View at Scopus
  77. J. Zou, M. Gan, N. Mao, X. Zhu, Q. Shi, and H. Yang, “Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin,” Archives of Medical Research, vol. 41, no. 3, pp. 162–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Huang, K. Liu, Y. Yu, et al., “Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma,” Autophagy, vol. 8, no. 2, pp. 275–277, 2012.
  79. J. Huang, J. Ni, K. Liu, et al., “HMGB1 promotes drug resistance in osteosarcoma,” Cancer Research, vol. 72, no. 1, pp. 230–238, 2012.
  80. N. V. Rao, B. Argyle, X. Xu et al., “Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands,” American Journal of Physiology, vol. 299, no. 1, pp. C97–C110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Sotillo-Piñeiro, L. Sierrasesúmaga, and A. Patiño-García, “Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients,” Pediatric Research, vol. 55, no. 2, pp. 231–235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Fujimori, T. Matsuo, S. Shimose et al., “Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines,” Journal of Orthopaedic Research, vol. 29, pp. 1707–1711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Takahashi, F. Higashino, M. Aoyagi et al., “EWS/ETS fusions activate telomerase in Ewing's tumors,” Cancer Research, vol. 63, no. 23, pp. 8338–8344, 2003. View at Scopus
  84. K. Trieb and H. Blahovec, “Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro,” International Journal of Biochemistry and Cell Biology, vol. 35, no. 7, pp. 1066–1070, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. O. Uziel, E. Fenig, J. Nordenberg et al., “Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines,” British Journal of Cancer, vol. 92, no. 10, pp. 1881–1891, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. C. Lanvers-Kaminsky, B. Winter, S. Koling et al., “Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo,” Oncology Reports, vol. 14, no. 3, pp. 751–758, 2005. View at Scopus
  87. A. Schuck, C. Poremba, C. Lanvers et al., “Radiation-induced changes of telomerase activity in a human Ewing xenograft tumor,” Strahlentherapie und Onkologie, vol. 178, no. 12, pp. 701–708, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. K. S. Stewart and E. S. Kleinerman, “Tumor vessel development and expansion in Ewing's sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents,” Sarcoma, vol. 2011, Article ID 165837, 7 pages, 2011. View at Publisher · View at Google Scholar
  89. H. Mizobuchi, J. M. García-Castellano, S. Philip, J. H. Healey, and R. Gorlick, “Hypoxia markers in human osteosarcoma: an exploratory study,” Clinical Orthopaedics and Related Research, vol. 466, no. 9, pp. 2052–2059, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Bajpai, M. Sharma, V. Sreenivas et al., “VEGF expression as a prognostic marker in osteosarcoma,” Pediatric Blood and Cancer, vol. 53, no. 6, pp. 1035–1039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. Q. C. Yang, B. F. Zeng, Z. M. Shi et al., “Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 4, pp. 593–599, 2006. View at Scopus
  92. D. N. T. Aryee, S. Niedan, M. Kauer et al., “Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's Sarcoma cells In vitro,” Cancer Research, vol. 70, no. 10, pp. 4015–4023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. Q. C. Yang, B. F. Zeng, Y. Dong, Z. M. Shi, Z. M. Jiang, and J. Huang, “Overexpression of hypoxia-inducible factor-1α in human osteosarcoma: correlation with clinicopathological parameters and survival outcome,” Japanese Journal of Clinical Oncology, vol. 37, no. 2, pp. 127–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. H. J. Knowles, K. L. Schaefer, U. Dirksen, and N. A. Athanasou, “Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor,” BMC Cancer, vol. 10, article 372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. J. M. Maris, J. Courtright, P. J. Houghton et al., “Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 581–587, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. C. L. Morton, J. M. Maris, S. T. Keir, et al., “Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program,” Pediatric Blood & Cancer, vol. 58, no. 4, pp. 566–571, 2012.
  97. E. Pencreach, E. Guérin, C. Nicolet et al., “Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-lnducible factor-1α axis,” Clinical Cancer Research, vol. 15, no. 4, pp. 1297–1307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. J. PosthumaDeBoer, M. A. Witlox, G. J. Kaspers, and B. J. van Royen, “Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature,” Clinical and Experimental Metastasis, vol. 28, no. 5, pp. 493–503, 2011.
  99. D. P. M. Hughes, “How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize,” Cancer Treatment and Research, vol. 152, pp. 479–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Baliko, T. Bright, R. Poon, B. Cohen, S. E. Egan, and B. A. Alman, “Inhibition of notch signaling induces neural differentiation in Ewing sarcoma,” American Journal of Pathology, vol. 170, no. 5, pp. 1686–1694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. D. J. Deangelo, R. M. Stone, L. B. Silverman, et al., “A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias,” Journal of Clinical Oncology, vol. 24, 8S, abstract 6585, ASCO Annual Meeting Proceedings Part I, 2006.
  102. M. Fouladi, C. F. Stewart, J. Olson, et al., “Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study,” Journal of Clinical Oncology, vol. 29, no. 26, pp. 3529–3534, 2011.
  103. N. Coltella, M. C. Manara, V. Cerisano et al., “Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma,” The FASEB Journal, vol. 17, no. 9, pp. 1162–1164, 2003. View at Scopus
  104. N. Entz-Werle, T. Lavaux, N. Metzger et al., “Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis,” Neoplasia, vol. 9, no. 8, pp. 678–688, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. A. T. Liao, J. McCleese, S. Kamerling, J. Christensen, and C. A. London, “A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma,” Veterinary and Comparative Oncology, vol. 5, no. 3, pp. 177–196, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. E. R. Sampson, B. A. Martin, A. E. Morris et al., “The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model,” Journal of Bone and Mineral Research, vol. 26, no. 6, pp. 1283–1294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Cai, A. B. Mohseny, M. Karperien, P. C. W. Hogendoorn, G. Zhou, and A. M. Cleton-Jansen, “Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma,” Journal of Pathology, vol. 220, no. 1, pp. 24–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. L. H. Brail, J. E. Gray, H. Burris, et al., “A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin,” Journal of Clinical Oncology, vol. 29, 15s, supplement, abstract 3030, 2011.
  109. L. L. Worth, E. A. Lafleur, S. F. Jia, and E. S. Kleinerman, “Fas expression inversely correlates with metastatic potential in osteosarcoma cells,” Oncology Reports, vol. 9, no. 4, pp. 823–827, 2002. View at Scopus
  110. K. Krishnan, C. Khanna, and L. J. Helman, “The biology of metastases in pediatric sarcomas,” Cancer Journal, vol. 11, no. 4, pp. 306–313, 2005. View at Scopus
  111. X. Wan, S. Y. Kim, L. M. Guenther et al., “Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin,” Oncogene, vol. 28, no. 38, pp. 3401–3411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. I. Tsagaraki, E. C. Tsilibary, and A. K. Tzinia, “TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis,” Cell and Tissue Research, vol. 342, no. 1, pp. 87–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. T. J. MacDonald, C. F. Stewart, M. Kocak et al., “Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 919–924, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. G. De Angulo, M. Hernandez, J. Morales-Arias et al., “Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 1, pp. 48–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. C. Moore, D. Eslin, A. Levy, J. Roberson, V. Giusti, and R. Sutphin, “Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma,” Pediatric Blood and Cancer, vol. 55, no. 6, pp. 1096–1102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Sancéau, M. F. Poupon, O. Delattre, X. Sastre-Garau, and J. Wietzerbin, “Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide,” Oncogene, vol. 21, no. 50, pp. 7700–7709, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Sancéau and J. Wietzerbin, “Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-α or interferon-β with ifosfamide,” Annals of the New York Academy of Sciences, vol. 1030, pp. 170–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. D. Berghuis, S. J. Santos, H. J. Baelde et al., “Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression,” Journal of Pathology, vol. 223, no. 3, pp. 347–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Fujiwara, J. Fukushi, S. Yamamoto, et al., “Macrophage infiltration predicts a poor prognosis for human ewing sarcoma,” American Journal of Pathology, vol. 179, no. 3, pp. 1157–1170, 2011.
  120. N. Gaspar, A. Rey, P. M. Bérard, et al., “Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study,” European Journal of Cancer, vol. 48, no. 9, pp. 1376–1385, 2012.
  121. B. Liu, Z. L. Shi, J. Feng, and H. M. Tao, “Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt,” Cell Biology International, vol. 32, no. 5, pp. 494–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. A. S. Gendy, A. Lipskar, R. D. Glick, B. M. Steinberg, M. Edelman, and S. Z. Soffer, “Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma,” Journal of Pediatric Surgery, vol. 46, no. 1, pp. 108–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Lipinski, K. Braham, and I. Philip, “Neuroectoderm-associated antigens on Ewing's sarcoma cell lines,” Cancer Research, vol. 47, no. 1, pp. 183–187, 1987. View at Scopus
  124. J. P. Heiner, F. Miraldi, S. Kallick et al., “Localization of G(D2)-specific monoclonal antibody 3F8 in human osteosarcoma,” Cancer Research, vol. 47, no. 20, pp. 5377–5381, 1987. View at Scopus
  125. A. L. Yu, A. L. Gilman, M. F. Ozkaynak, et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010.
  126. A. L. Yu, M. M. Uttenreuther-Fischer, C. S. Huang et al., “Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma,” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2169–2180, 1998. View at Scopus
  127. S. Kailayangiri, B. Altvater, J. Meltzer, et al., “The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting,” British Journal of Cancer, vol. 106, no. 6, pp. 1123–1133, 2012.
  128. E. K. Waller, “The role of sargramostim (rhGM-CSF) as immunotherapy,” Oncologist, vol. 12, no. 2, pp. 22–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. C. A. S. Arndt, N. V. Koshkina, C. Y. Inwards et al., “Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group,” Clinical Cancer Research, vol. 16, no. 15, pp. 4024–4030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. F. Meyer-Wentrup, G. Richter, and S. Burdach, “Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope,” Pediatric Hematology and Oncology, vol. 22, no. 4, pp. 297–308, 2005. View at Publisher · View at Google Scholar · View at Scopus
  131. T. Kubo, S. Shimose, T. Matsuo, J. Fujimori, K. Arihiro, and M. Ochi, “Interferon-α/β receptor as a prognostic marker in osteosarcoma,” Journal of Bone and Joint Surgery Series A, vol. 93, no. 6, pp. 519–526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. E. P. Buddingh, M. L. Kuijjer, R. A. J. Duim et al., “Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents,” Clinical Cancer Research, vol. 17, no. 8, pp. 2110–2119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Whelan, D. Patterson, M. Perisoglou et al., “The role of interferons in the treatment of osteosarcoma,” Pediatric Blood and Cancer, vol. 54, no. 3, pp. 350–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. Z. Li, Q. Xu, H. Peng, R. Cheng, Z. Sun, and Z. Ye, “IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway,” International Immunopharmacology, vol. 11, no. 4, pp. 496–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. L. Kager, U. Potschger, S. Bielack, et al., “Review of mifamurtide in the treatment of patients with osteosarcoma,” Therapeutics and Clinical Risk Management, vol. 6, pp. 279–286, 2010.
  136. Y. Wittrant, S. Théoleyre, C. Chipoy et al., “RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis,” Biochimica et Biophysica Acta, vol. 1704, no. 2, pp. 49–57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. D. H. Jones, T. Nakashima, O. H. Sanchez et al., “Regulation of cancer cell migration and bone metastasis by RANKL,” Nature, vol. 440, no. 7084, pp. 692–696, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Avnet, A. Longhi, M. Salerno et al., “Increased osteoclast activity is associated with aggressiveness of osteosarcoma,” International Journal of Oncology, vol. 33, no. 6, pp. 1231–1238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. J. A. Lee, J. S. Jung, D. H. Kim et al., “RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma,” Pediatric Blood and Cancer, vol. 56, no. 5, pp. 738–743, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. Z. Zhou, H. Guan, X. Duan, and E. S. Kleinerman, “Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma,” Cancer, vol. 104, no. 8, pp. 1713–1720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. R. Tenta, N. Pitulis, D. Tiblalexi et al., “Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells,” Hormone and Metabolic Research, vol. 40, no. 11, pp. 737–745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. T. Iguchi, Y. Miyakawa, K. Saito et al., “Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells,” International Journal of Oncology, vol. 31, no. 2, pp. 285–291, 2007. View at Scopus
  143. B. Ory, F. Blanchard, S. Battaglia, F. Gouin, F. Rédini, and D. Heymann, “Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status,” Molecular Pharmacology, vol. 71, no. 1, pp. 333–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. A. Evdokiou, A. Labrinidis, S. Bouralexis, S. Hay, and D. M. Findlay, “Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis,” Bone, vol. 33, no. 2, pp. 216–228, 2003. View at Publisher · View at Google Scholar · View at Scopus
  145. D. Fu, X. He, S. Yang, W. Xu, T. Lin, and X. Feng, “Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro,” BMC Musculoskeletal Disorders, vol. 12, article 146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. D. Heymann, B. Ory, F. Blanchard et al., “Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma,” Bone, vol. 37, no. 1, pp. 74–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Labrinidis, S. Hay, V. Liapis, D. M. Findlay, and A. Evdokiou, “Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model,” International Journal of Cancer, vol. 127, no. 2, pp. 345–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. C. R. Dass and P. F. M. Choong, “Zoledronic acid inhibits osteosarcoma growth in an orthotopic model,” Molecular Cancer Therapeutics, vol. 6, no. 12, pp. 3263–3270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. K. Koto, N. Horie, S. Kimura et al., “Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model,” Cancer Letters, vol. 274, no. 2, pp. 271–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. L. Endo-Munoz, A. Cumming, D. Rickwood et al., “Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases,” Cancer Research, vol. 70, no. 18, pp. 7063–7072, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. M. S. Benassi, A. Chiechi, F. Ponticelli et al., “Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells,” Cancer Letters, vol. 250, no. 2, pp. 194–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Ryu, H. Murata, K. Koto et al., “Combined effects of bisphosphonate and radiation on osteosarcoma cells,” AntiCancer Research, vol. 30, no. 7, pp. 2713–2720, 2010. View at Scopus
  153. G. A. Odri, S. Dumoucel, G. Picarda et al., “Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients,” Cancer Research, vol. 70, no. 19, pp. 7610–7619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Battaglia, S. Dumoucel, J. Chesneau, et al., “Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient,” Journal of Bone and Mineral Research, vol. 26, no. 10, pp. 2439–2451, 2011.
  155. T. Akiyama, C. R. Dass, Y. Shinoda, H. Kawano, S. Tanaka, and P. F. M. Choong, “Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts,” Journal of Pharmacy and Pharmacology, vol. 62, no. 4, pp. 470–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. F. Lamoureux, G. Picarda, J. Rousseau et al., “Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3389–3398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. F. Lamoureux, P. Richard, Y. Wittrant et al., “Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption,” Cancer Research, vol. 67, no. 15, pp. 7308–7318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. J. Rousseau, V. Escriou, F. Lamoureux, et al., “Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models,” Journal of Bone and Mineral Research, vol. 26, no. 10, pp. 2452–2462, 2011.
  159. H. Guan, Z. Zhou, Y. Cao, X. Duan, and E. S. Kleinerman, “VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL,” Oncology Research, vol. 18, no. 2-3, pp. 117–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. R. Taylor, H. J. Knowles, and N. A. Athanasou, “Ewing sarcoma cells express RANKL and support osteoclastogenesis,” Journal of Pathology, vol. 225, no. 2, pp. 195–202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. K. Fizazi, A. Lipton, X. Mariette et al., “Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1564–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  162. D. Thomas, S. P. Chawla, K. Skubitz, et al., “Denosumab treatment of giant cell tumor of bone: interim analysis of an open-label phase II study,” Journal of Clinical Oncology, vol. 26, supplement, abstract 10500, 2008.
  163. G. Henriksen, K. Breistøl, Ø. S. Bruland, Ø. Fodstad, and R. H. Larsen, “Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model,” Cancer Research, vol. 62, no. 11, pp. 3120–3125, 2002. View at Scopus
  164. P. Anderson and R. Nuñez, “Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma,” Expert Review of Anticancer Therapy, vol. 7, no. 11, pp. 1517–1527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  165. D. M. Loeb, R. F. Hobbs, A. Okoli et al., “Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma,” Cancer, vol. 116, no. 23, pp. 5470–5478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. C. Parker, S. Nilsson, D. Heinrich, et al., “Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA),” Journal of Clinical Oncology, vol. 30, supplement, abstract LBA4512, 2012.
  167. M. Hirotsu, T. Setoguchi, H. Sasaki et al., “Smoothened as a new therapeutic target for human osteosarcoma,” Molecular Cancer, vol. 9, article 5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. E. M. Beauchamp, L. Ringer, G. Bulut et al., “Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 148–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. J. Warzecha, S. Göttig, K. U. Chow et al., “Inhibition of osteosarcoma cell proliferation by the hedgehog-inhibitor cyclopamine,” Journal of Chemotherapy, vol. 19, no. 5, pp. 554–561, 2007. View at Scopus
  170. H. Zhao, W. Guo, C. Peng, T. Ji, and X. Lu, “Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis,” Molecular Biology Reports, vol. 37, no. 5, pp. 2509–2515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Kim, J. Y. Tang, R. Gong et al., “Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth,” Cancer Cell, vol. 17, no. 4, pp. 388–399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. M. Fouladi, J. R. Park, C. F. Stewart et al., “Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3623–3629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. J. M. Su, X. N. Li, P. Thompson et al., “Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report,” Clinical Cancer Research, vol. 17, no. 3, pp. 589–597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. T. Hirose, Y. Sowa, S. Takahashi et al., “p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y,” Oncogene, vol. 22, no. 49, pp. 7762–7773, 2003. View at Publisher · View at Google Scholar · View at Scopus
  175. C. Blattmann, S. Oertel, V. Ehemann, et al., “Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition,” International Journal of Radiation Oncology, Biology, Physics, vol. 78, no. 1, pp. 237–245, 2010.
  176. L. A. Wittenburg, L. Bisson, B. J. Rose, C. Korch, and D. H. Thamm, “The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 83–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. C. Yang, E. Choy, F. J. Hornicek et al., “Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 2, pp. 439–446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. N. V. Koshkina, K. Rao-Bindal, and E. S. Kleinerman, “Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases,” Cancer, vol. 117, no. 15, pp. 3457–3467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. K. Watanabe, K. Okamoto, and S. Yonehara, “Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP,” Cell Death and Differentiation, vol. 12, no. 1, pp. 10–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  180. K. Yamanegi, J. Yamane, K. Kobayashi et al., “Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity,” Oncology Reports, vol. 24, no. 6, pp. 1621–1627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  181. R. Sakimura, K. Tanaka, F. Nakatani et al., “Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors,” International Journal of Cancer, vol. 116, no. 5, pp. 784–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  182. F. Nakatani, K. Tanaka, R. Sakimura et al., “Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 15105–15115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  183. J. Sonnemann, L. Dreyer, M. Hartwig et al., “Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells,” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 11, pp. 847–858, 2007. View at Publisher · View at Google Scholar · View at Scopus
  184. T. Okada, K. Tanaka, F. Nakatani et al., “Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells,” International Journal of Cancer, vol. 118, no. 1, pp. 90–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  185. H. Matsubara, M. Watanabe, T. Imai et al., “Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S, 4S, 7Z, 10S, 16E, 21R)-7- ethylidene-4, 21-bis(propan-2-yl)-2-oxa-12, 13-dithia-5, 8, 20, 23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone],” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 3, pp. 839–848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. A. S. Martins, J. L. Ordoñez, A. García-Sánchez et al., “A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study,” Cancer Research, vol. 68, no. 15, pp. 6260–6270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  187. R. Bagatell, J. Beliakoff, C. L. David, M. T. Marron, and L. Whitesell, “Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin,” International Journal of Cancer, vol. 113, no. 2, pp. 179–188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  188. N. Gaspar, S. Y. Sharp, S. Pacey et al., “Acquired resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-A AG, Tanespimycin) in glioblastoma cells,” Cancer Research, vol. 69, no. 5, pp. 1966–1975, 2009. View at Publisher · View at Google Scholar · View at Scopus